X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 60 filers reported holding X4 PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 2.88 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $677,318 | +123.0% | 349,133 | 0.0% | 0.11% | +56.5% |
| Q1 2023 | $303,745 | -12.4% | 349,133 | 0.0% | 0.07% | -17.9% |
| Q4 2022 | $346,689 | -64.4% | 349,133 | -38.6% | 0.08% | -56.7% |
| Q3 2022 | $973,000 | -40.0% | 568,612 | -66.1% | 0.19% | -34.5% |
| Q2 2022 | $1,621,000 | -32.5% | 1,679,748 | +22.4% | 0.30% | -6.3% |
| Q1 2022 | $2,402,000 | -53.7% | 1,372,022 | -39.4% | 0.32% | -59.1% |
| Q4 2021 | $5,186,000 | -61.4% | 2,264,491 | -10.8% | 0.77% | -18.3% |
| Q3 2021 | $13,437,000 | -24.0% | 2,539,917 | -6.6% | 0.95% | -33.8% |
| Q2 2021 | $17,676,000 | -21.5% | 2,719,290 | +4.0% | 1.43% | +88.5% |
| Q1 2021 | $22,515,000 | +323.7% | 2,614,988 | +216.4% | 0.76% | +223.9% |
| Q4 2020 | $5,314,000 | +8.3% | 826,424 | +14.0% | 0.23% | -34.1% |
| Q3 2020 | $4,907,000 | +10340.4% | 724,680 | +14393.6% | 0.36% | +8775.0% |
| Q2 2020 | $47,000 | -56.1% | 5,000 | -50.0% | 0.00% | -76.5% |
| Q4 2019 | $107,000 | – | 10,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 6,247,500 | $6,809,775 | 2.18% |
| Bain Capital Life Sciences Investors, LLC | 15,960,588 | $17,397,041 | 1.94% |
| Stonepine Capital Management, LLC | 5,273,685 | $5,748,317 | 1.91% |
| NEA Management Company, LLC | 14,986,793 | $16,335,604 | 1.26% |
| Sio Capital Management, LLC | 2,599,003 | $2,832,913 | 0.88% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $365,150 | 0.47% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,973,683 | $2,151,314 | 0.25% |
| Monashee Investment Management LLC | 427,265 | $465,719 | 0.20% |
| Orbimed Advisors | 7,133,515 | $7,775,531 | 0.16% |
| Parkman Healthcare Partners LLC | 800,000 | $872,000 | 0.16% |